Christian Bréchot Appointed to bioMérieux's Board

Vice President of Medical and Scientific Affairs at Mérieux Alliance since January 2008, Professor Bréchot was the Director General of INSERM* between 2001 and 2007.

A specialist of liver diseases, he was in charge of the Pasteur Institute’s National Reference Center for the molecular epidemiology of viral hepatitis between 1998 and 2001. From 1993-2001, he was director of the INSERM U370/University Paris V research unit “Hepatocellular Carcinogenesis and Molecular Virology” at the Necker School of Medicine. He was also head of the Liver Unit at the Necker-Enfants Malades hospital from 1997-2001, and head of the Cell Biology department at the Necker School of Medicine.

Christian Bréchot, 55 years old, is a University Professor of Cell Biology and a Hospital Practitioner in Hepatology. After studying medicine at the Broussais-Hôtel Dieu School of Medicine in Paris, he received both clinical training in hepatology and research training, in the areas of molecular biology, virology and cellular biology, at the Pasteur Institute of Paris.

He has developed several diagnostic tests and will bring his expertise in research, predictive medicine and public health to the bioMérieux Board.

* Institut national de la santé et de la recherche médicale (French national health and medical research institute)

About bioMérieux

Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for 45 years, bioMérieux is present in more than 150 countries through 38 subsidiaries and a large network of distributors. In 2007, revenues reached €1.063 billion with 84% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies and cancer screening and monitoring. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the NYSE Euronext Paris market (Code: BIM – Code ISIN: FR0010096479). Other information can be found at http://www.biomerieux.com/.

bioMérieux Contacts

Investor Relations

bioMérieux
Isabelle Tongio
Tel: + 33 4 78 87 22 37
investor.relations@eu.biomerieux.com

LT Value
Nancy Levain
Tel: + 33 1 55 27 15 88
nancy.levain@ltvalue.com

Media Relations

bioMérieux
Koren Wolman-Tardy
Tel: + 33 4 78 87 20 08
media@eu.biomerieux.com

Image Sept
Laurence Heilbronn
Tel: + 33 1 53 70 74 64
lheilbronn@image7.fr